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Abstract
Background: Western European porcine reproductive and respiratory syndrome virus (PRRSV) strains cause limited
and mild clinical signs whereas more virulent strains are circulating in Eastern Europe. The emergence of such
highly virulent strains in Western Europe might result in severe clinical problems and a financial disaster. In this
context, the efficacy of the commercial modified-live PRRSV subtype 1 vaccine UNISTRAIN® PRRS was tested upon
challenge with the East European subtype 3 PRRSV strain Lena.
Results: The mean duration of fever was shortened and the number of fever days was significantly lower in
vaccinated pigs than in control pigs. Moreover, a lower number of vaccinated animals showed fever, respiratory
disorders and conjunctivitis. The mean virus titers in the nasal secretions post challenge (AUC) were significantly
lower in the vaccinated group than in the control group. The duration of viremia was slightly shorter (not
significantly different) in the vaccinated group as compared to the control group.
Conclusions: Vaccination of pigs with the modified-live vaccine UNISTRAIN® PRRS provides a partial clinical and
virological protection against the PRRSV subtype 3 strain Lena.
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Background
Porcine Reproductive and Respiratory Syndrome (PRRS),
originally designated Mystery Swine Disease, was first rec-
ognized in the United States in the late 1980s and is char-
acterized by late abortion, stillbirth, weak piglets and
mummies and is associated with the porcine respiratory
disease complex [1]. In 1991, an arterivirus was identified
as etiological agent and was scientifically called Porcine
Reproductive and Respiratory Syndrome Virus (PRRSV)
[2]. During two decades, the virus and its pathogenesis
have been studied in-depth, which brought many new in-
sights. There are two main genotypes: the European geno-
type (genotype 1) and the North American genotype
(genotype 2). Three (potentially four) subtypes were
already distinguished within the European PRRSV geno-
type 1 [3]. Subtype 1 is only present in the EU whereas in
the Russian area all three (four) subtypes are circulating.
After infection with subtype 1, limited clinical signs and
respiratory disorders are observed in growing pigs [4, 5].
In contrast, subtypes 2 and 3 are more virulent and infec-
tion with subtype 3 strain Lena results in rapid onset of
disease with high fever, severe dyspnea and tachypnea,
periorbital oedema, depression and mortality [6, 7].
To prevent PRRS, several live-attenuated and inacti-
vated vaccines against PRRSV are commercially available.
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Attenuated vaccines significantly shorten the viremic
phase post challenge [8], but there are concerns on rever-
sion to virulence and the low level of protection upon
challenge with heterologous PRRSV strains [9]. Commer-
cial inactivated vaccines are safe, but are not providing a
sufficient level of protection [8, 10]. Despite several at-
tempts, no vaccine is providing full protection against the
currently circulating PRRSV strains [11]. This might be
explained by the low antigenic degree of similarity be-
tween the vaccine and challenge strain and the immune
evasive character of the virus [12–14]. The co-existence of
different subtypes in Europe emphasizes the need for
cross-protective vaccines.
Until recently no information was available concerning
the efficacy of PRRSV subtype 1 vaccines against PRRSV
subtype 3 strains, such as Lena. Surprisingly, a commer-
cially available attenuated subtype 1 vaccine, based on
the DV strain, offered partial protection upon the East
European strain [15]. This positive result led to the
present study, where the clinical and virological protec-
tion of another commercially available attenuated sub-
type 1 vaccine, based on a Spanish PRRSV isolate, was
evaluated upon infection with the virulent subtype 3
PRRSV strain Lena.
Results
Clinical signs after vaccination and challenge
After vaccination - No adverse local or systemic effects
were observed upon vaccination.
After challenge - The effect of vaccination on body
temperature upon challenge is presented in Fig. 1. Over-
all, a slight beneficial effect of vaccination was observed.
In brief, the mean body temperature in control pigs was
higher compared to vaccinated animals between 6 and
13 days post challenge (dpc), although the difference
was not statistically significant. Also, the area under the
curve (AUC) value of fever (with a threshold at 40.0 °C)
was higher in the non-vaccinated group (11.7 ± 2.2) than
in the vaccinated group (9.7 ± 1.4). A significant benefi-
cial effect was observed for the number of fever days, i.e.
the total number of days that an animal showed fever
throughout the observation period (9.2 ± 2.9 days for
control animals versus 5.2 ± 1.9 days for the vaccinated
animals). Also, the number of animals that showed fever
per day throughout the observation period was signifi-
cantly lower in the vaccinated group. Mild respiratory
disorders were observed from 2 dpc in non-vaccinated
animals and from 5 dpc in vaccinated animals. All ani-
mals, except for one unvaccinated pig, showed respira-
tory signs at least at one time point during the
observation period. Respiratory disorders lasted up till
3 weeks post challenge. Scores ranged from 1 to 6 in
non-vaccinated animals and from 1 to 4 in vaccinated
animals. No significant differences were observed in the
mean respiratory score between both groups throughout
the study. The AUC value was not significantly higher in
the non-vaccinated group (16.1 ± 12.6) than in the vacci-
nated animals (9.0 ± 9.5). A significant beneficial effect
was observed for the number of animals that showed
Fig. 1 Body temperature after challenge with PRRSV subtype 3 strain Lena. Bullets represent individual animals; lines represent the mean body
temperature in each group. Solid bullets and solid line show the body temperature for the control group; open bullets and dashed line show the body
temperature for the vaccinated group. Dotted line represents the threshold for fever (40.0 °C)
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respiratory signs per day throughout the observation
period. A slight reduction in liveliness was observed
from 2 dpc in non-vaccinated animals and 5 dpc in vac-
cinated animals and lasted up till 3 weeks post challenge.
All animals showed a reduced activity at least at two
time points during the observation period and the re-
duction in liveliness was associated with the occurrence
of fever. Discoloration of the ears was regularly observed
in all control animals from 6 dpc up till the end of the
experiment. In the vaccinated group, mild discoloration
of the ears was observed in 4 out of 5 animals between 7
and 17 dpc. Clinical disorders of the eyes, such as con-
junctivitis, were seen from 5 dpc in unvaccinated
animals and from 6 dpc in vaccinated animals. All non-
vaccinated animals showed mild conjunctivitis at least at
two time points during the observation period. Only
three out of five vaccinated animals showed mild con-
junctivitis at least at one time point during the observa-
tion period. The AUC value was significantly higher in
the non-vaccinated group (3.0 ± 1.7) than in vaccinated
animals (0.6 ± 0.7). A significant beneficial effect was also
observed for the number of days at which conjunctivitis
was observed (6.0 ± 3.3 days for control animals versus
1.2 ± 1.3 days for vaccinated animals). In general, all pigs
showed a similar growth rate, independently of vaccin-
ation. Mean body weight in the non-vaccinated group at
arrival, challenge and euthanasia was 8.1 ± 0.8 kg, 17.9 ±
3.4 kg and 28.8 ± 6.4 kg, respectively. At the same time
points, body weight of the animals in the vaccinated
group was 8.6 ± 1.0 kg, 15.4 ± 2.7 kg and 27.4 ± 3.9 kg,
respectively. At necropsy (28 dpc), macroscopic lung le-
sions were found in 3/6 control pigs and in 2/5 vacci-
nated pigs. The total affected lung area in these pigs
varied from 0.1 to 0.6 % (control group) and from 0.1 to
2.6 % (vaccinated group). The mean total affected lung
area was not significantly different between the groups.
Serological response upon vaccination and challenge
At the time of arrival (-35 dpc), all pigs were serologic-
ally and virologically negative for PRRSV, as determined
by immunoperoxidase monolayer assay (IPMA) and
virus titration.
Figure 2 represents the evolution of the IPMA anti-
body titers during the course of the experiment in vacci-
nated and unvaccinated control pigs. All control pigs
remained seronegative until challenge. The vaccinated
pigs seroconverted within two weeks after vaccination
with a titer of 3.2 ± 0.8 log10 at -7 dpc. After challenge,
an increase in IPMA antibody titers was observed in all
animals within two weeks. Figure 3 represents the evolu-
tion of the virus neutralizing (VN) antibody titers against
PRRSV. In both vaccinated and control groups, VN anti-
bodies against PRRSV LV were not detected before chal-
lenge. After challenge, VN antibodies against PRRSV
Lena were only detected in one out of five vaccinated
animals at very low titers (≤3 log2) at 21 dpc. A similar
pattern in ELISA antibodies was observed as for IPMA
antibodies.
Fig. 2 IPMA antibody titers upon vaccination with PRRSV subtype 1 vaccine UNISTRAIN® PRRS and challenge with PRRSV subtype 3 strain Lena.
Bullets represent individual animals; lines represent the mean titer in each group. Solid bullets and solid line show the titer for the control group;
open bullets and dashed line show the titer for the vaccinated group. Dotted line represents the detection limit for the test
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Protective effect of vaccination against viral shedding
Significant differences were found in viral shedding in
nasal secretions. Viral shedding was observed from 3
dpc in both groups (Fig. 4). Titers peaked between 3 and
7 dpc in the control group and at 5 dpc in the vacci-
nated group. Peak mean titers were 5.6 ± 0.8 log10 tissue
culture infectious dose with 50 % end point (TCID50)/
100 mg and 5.0 ± 0.3 log10 TCID50/100 mg, respectively.
In the control group, virus shedding was observed until
at least 28 dpc (end of the experiment) with one out of
six pigs still shedding virus (1.5 log10 TCID50/100 mg).
In the five vaccinated pigs, viral shedding was observed
in all animals up till 10 dpc. After that, two animals shed
virus up till 28 dpc. Significant differences in virus titers
were found at 3, 7 and 10 dpc. Moreover, the AUC value
of virus secretion was significantly lower in the vacci-
nated pigs (11.6 ± 3.5) than in the non-vaccinated pigs
(18.4 ± 1.9).
Protective effect of vaccination against viremia
The results of virus titrations of sera (viremia) are shown
in Fig. 5. Virus was present in sera of all animals from 3
dpc. A peak was observed at 10 dpc in the control group
(4.2 ± 0.2 log10 TCID50/ml) and at 5 dpc in the vacci-
nated group (4.7 ± 0.6 log10 TCID50/ml). In the control
group, viremia lasted until at least 28 dpc (end of the ex-
periment) with two out of six piglets still being viremic,
although at low titers (2.1 and 1.6 log10 TCID50/ml). In
the vaccinated group, viremia lasted until 21 dpc. Des-
pite the shorter duration of viremia, no significant differ-
ences were observed in the mean virus titer between
control and vaccinated pigs. Also, no significant differ-
ences were seen for AUC values between both groups
(15.4 ± 0.8 in control animals versus 15.9 ± 2.0 in vacci-
nated animals).
Discussion
Reproductive failure with early farrowing, late abortion,
still- and weakborn piglets in sows and infertility in
boars on the one hand and respiratory disorders in
piglets on the other hand are hallmarks of PRRS. De-
pending on the strain genotype, host genotype and co-
infections, divergent clinical signs can be observed in
piglets. Pigs are well protected against a challenge or re-
infection with a homologous strain after a natural infec-
tion [8, 12, 16, 17]. This can be mimicked using
modified-live vaccines [18, 19]. However, after a heterol-
ogous challenge different levels of protection can be ob-
tained [16, 18–20]. In general, animals are partially
protected, both clinically and virologically. Labarque
et al. found evidence that a genetic diversity within
European strains of subtype 1 affects the efficacy of
European vaccines and similar findings were described
after natural exposure within the same subtype [12, 16].
In the present study, the efficacy of a vaccination with
UNISTRAIN® PRRS (genotype 1, subtype 1) was
Fig. 3 VN antibody titers upon vaccination with PRRSV subtype 1 vaccine UNISTRAIN® PRRS and challenge with PRRSV subtype 3 strain Lena.
Bullets represent individual animals; lines represent the mean titer in each group. Solid bullets and solid line show the titer for the control group;
open bullets and dashed line show the titer for the vaccinated group. Dotted line represents the detection limit for the test
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Fig. 5 Viremia after challenge with PRRSV subtype 3 strain Lena. Bullets represent individual animals; lines represent the mean titer in each group.
Solid bullets and solid line show the titer for the control group; open bullets and dashed line show the titer for the vaccinated group. Dotted line
represents the detection limit for the test
Fig. 4 Nasal viral shedding after challenge with PRRSV subtype 3 strain Lena. Bullets represent individual animals; lines represent the mean titer in
each group. Solid bullets and solid line show the titer for the control group; open bullets and dashed line show the titer for the vaccinated group.
Dotted line represents the detection limit for the test
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examined upon a challenge with PRRSV strain Lena
(genotype 1, subtype 3). The mean duration of fever was
shortened and the number of fever days was signifi-
cantly reduced in vaccinated pigs compared to unvac-
cinated control pigs. Scores for respiratory and eye
disorders were assigned to fewer vaccinated animals
than to control pigs. Based on these results, the vaccine
is considered to raise an immunity that gives a partial
clinical protection against heterologous infection. In
addition, the vaccination with UNISTRAIN® PRRS offers
also a partial virological protection. Significant differ-
ences in mean nasal PRRSV titers were observed at 3, 7
and 10 dpc and titers were reduced with 1.64, 2.29 and
2.14 log10 TCID50/100 mg, respectively. In addition, the
total nasal viral shedding (AUC) upon challenge was
significantly lowered with a factor 6.8. Similar findings
concerning nasal secretion after vaccination with a
commercially available live-attenuated vaccine based on
the DV strain upon challenge with PRRSV Lena were re-
cently described [15]. The high titers in nasal secretions
in control animals might have influenced the process of
viral shedding since transmission through viral shedding
is considered to be an efficient way of re-infecting pen
mates and is a measure of safety and efficacy of com-
mercially available vaccines. In present study, a sudden
drop in PRRSV-titer in nasal secretions is observed at
14 dpc in control animals, after which three control pigs
secrete the virus at 21 dpc. In the vaccinated group, one
piglet shed PRRSV again at 21 dpc. The ratio of 3 re-
infected control pigs and 1 re-infected vaccinated piglet
suggest the protective effect of vaccination, which is in
agreement with previous studies [21, 22], although this
experimental design did not allow us to determine the
transmission ratio. Despite the positive outcome for
nasal shedding, vaccination with UNISTRAIN® PRRS
only slightly reduced the duration of viremia. In the
study of Trus et al. [15], the viremia was significantly re-
duced upon challenge with PRRSV strain Lena in pigs
vaccinated with a commercially available live-attenuated
vaccine based on the DV strain. This difference in pro-
tection might be explained by different factors, such as
age and breed of the pigs, interval between vaccination
and challenge, vaccine and challenge virus titer and
antigenic homology between the vaccine strain and
challenge strain. Although the regions that are respon-
sible for the induction of neutralizing antibodies and
cellular immunity have been identified [23–28], there is
no clear correlation between genetic homology and
antigenic homology [12, 13, 15, 29]. Therefore, it is diffi-
cult to estimate the impact of slight genetic differences
on the immunogenicity of the vaccine virus and the pro-
tection upon challenge (PRRSV strains DV and Lena
have an identity of 88 % whereas VP-046 BIS and Lena
have an 82.5 % identity (ORF5)). The different outcomes
between both studies cannot be related to the genetic
background in our opinion, as the piglets came from the
same farm [30, 31]. The major difference between both
studies was the vaccination-challenge interval. In the
studies described by Trus et al. [15], the interval was 6
and 8 weeks, which is two and four weeks longer than
in the present experiment. After infection and vaccin-
ation with PRRSV, the immunity is slowly induced and
it has been shown that protection six or eight weeks
after vaccination is better than after four weeks [14].
The virus neutralizing (VN) antibodies have a crucial
role in prevention of disease caused by Equine Arteritis
Virus (EAV) in horses [32] and Lactate dehydrogenase-
elevating virus (LDV) in mice [33]. Similarly, inhibition
of the PRRSV replication can be achieved by VN anti-
bodies [34]. However, neutralizing antibodies appear late
after PRRSV infection [35] or vaccination with modified-
live PRRSV vaccines [8, 36]. Thus, it is not surprisingly
that in the present study no VN antibodies were
detected during the four-week vaccination-challenge
interval.
After a homologous challenge, the VN antibodies
against the challenge virus are boosted [8, 15, 36, 37] in
contrast with a genotypically heterologous challenge
where no VN antibodies against the challenge virus are
detected [38, 39]. After challenge with the subtype 3
strain Lena, VN antibodies against Lena were only de-
tected in one UNISTRAIN® PRRS-vaccinated animal
during 2 weeks. In a similar experiment using another
PRRSV subtype 1 vaccine, based on the DV strain, the
pigs developed VN antibodies against Lena 1-2 weeks
after a PRRSV Lena challenge. In this latter study, the
viremia was clearly more reduced compared to their
non-vaccinated control group, which might be explained
in part by the presence of the neutralizing antibodies.
However, in the present study, the pig that developed
VN antibodies against Lena did not show a shorter dur-
ation of viremia or nasal shedding. The role of VN anti-
bodies in protection is therefore again disputable [40].
Certain branches of the cell-mediated immunity are
most likely more important and can be assessed by
measuring interferon gamma (IFN-γ) producing cells
[41]. During this study, a test to determine the levels of
the IFN-γ was not available in our laboratory and was
therefore not assessed. We do agree that those results
could have given an extra value and are implementing
this technique in current studies.
Conclusions
The present study demonstrates that vaccination with
the modified-live vaccine UNISTRAIN® PRRS provides a
partial clinical and virological protection upon challenge
with PRRSV Lena. Because only a partial clinical and
virological protection has been obtained with currently
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commercially available subtype 1 PRRSV vaccines, there




Eleven piglets were purchased from a PRRSV-negative
farm immediately after weaning. Their negative PRRSV
status was confirmed by serology (IPMA) and by virus
titration of sera and nasal secretions that were collected
upon arrival. They were acclimatized during seven days
after which the animals were randomly assigned to two
groups. One group (n = 5) was vaccinated intramuscu-
larly with 2 ml of the commercially available live attenu-
ated PRRSV subtype 1 vaccine (UNISTRAIN® PRRS,
Laboratorios Hipra S.A.). Retitration revealed a titer of
6.8 log10 TCID50 per ml. The second group was mock-
vaccinated with phosphate buffered saline (PBS) (n = 6).
At 4 weeks post vaccination, all pigs were intranasally
inoculated with 2 ml of 5 log10 TCID50 PRRS virus strain
Lena (subtype 3) [6]. Blood was collected on a weekly
base to monitor the serological status (IPMA and VN).
To follow the course of viremia and nasal shedding
upon challenge, blood and nasal swabs were collected
on 0, 3, 5, 7, 10, 14, 21 and 28 dpc. At 4 weeks post
challenge, the experiment was terminated by intravenous
injection of an overdose of sodium pentobarbital
(Natrium pentobarbital 20 %, Kela Laboratoria nv,
Hoogstraten, Belgium).
Serology
Fixed PRRSV Lelystad virus (LV) respectively Lena in-
fected Marc-145 cells in 96-well microtiter plates were
used for the IPMA [4]. Serial twofold dilutions of the
serum samples were added to the plates and incubated
for 1 hour at 37 °C. After washing, secondary goat anti-
swine IgG labeled with peroxidase were added for
another hour at 37 °C. Plates were washed again and a
substrate solution of 3-amino-9-ethylcarbazole (AEC)
was added to each well, followed by incubation of the
plates at room temperature for 20 minutes. The IPMA
titer is the reciprocal of the highest dilution that gives a
coloration of infected cells. VN antibodies were detected
by SN assays in Marc-145 cells using PRRSV LV in sera
collected before challenge and PRRSV Lena in sera col-
lected after challenge. Twofold dilutions of serum sam-
ples were prepared and 100 μl of the appropriate PRRSV
strain with a titer of 2 log10 TCID50/50 μl was added.
After mixing, the plates were incubated at 37 °C for
1 hour and 50 μl of the mixture was subsequently trans-
ferred to confluent monolayers of Marc-145 cells in 96-
well microtiter plates. Cells were screened for 7 days
after inoculation and the neutralization titer of the sera
was recorded as the reciprocal of the highest dilution
that inhibited CPE in 50 % of the inoculated wells. Add-
itionally, sample to positive ratios were determined using
the CIVTEST SUIS PRRS E/S® ELISA (Laboratorios
Hipra S.A.) with the aim to detect antibodies against
European PRRSV isolates. The ELISA was performed ac-
cording to the manufacturer’s instructions.
Evaluation of clinical signs
Body weight was monitored for all pigs upon arrival (-35
dpc), at challenge (0 dpc) and at euthanasia (28 dpc).
Local side effects as well as body temperature were re-
corded at 1, 2 and 3 days post vaccination (dpv). After
challenge, the animals were monitored daily for the pres-
ence of clinical signs up till day 14 post challenge, with
particular attention to PRRS related clinical signs. Clin-
ical parameters included body temperature, respiratory
symptoms, liveliness, discoloration of the ears, clinical
symptoms at the eyes and presence of diarrhea. A score
was assigned to the various parameters to allow an ob-
jective comparison between both groups. The scores
were based on the methodology described by Karniy-
chuk et al. [6] and Weesendorp et al. [7]. Lungs were
collected and macroscopic lung lesions were given a
score by visual observation and computer-assisted ana-
lysis. The percentage of lung surface affected by pneu-
monia was estimated by multiplying the lung lesion
score per lobe with the relative proportion of this lobe
in the entire lung [42].
Virus titrations
At 0, 3, 5, 7, 10, 14, 21 and 28 dpc, serum was tested
virologically (titration) to follow the course of viremia.
In addition, nasal secretions were collected with dry
swabs (COPAN 160C®), 1 ml transport medium (phos-
phate buffered saline supplemented with antibiotics and
fetal calf serum) was added and the swabs were vortexed
and centrifuged. Supernatant was used for virus titration.
In brief, porcine alveolar macrophages (PAM) were cul-
tivated for 24 hours and inoculated with 10-fold dilu-
tions of either serum or nasal secretion. After 72 hours,
cells were fixed and virus-infected cells were subse-
quently evaluated by subsequent incubation with
PRRSV-specific monoclonal antibodies against the nu-
cleocapsid protein.
Ethics statement
The study was conducted in compliance with the provi-
sions of Directive 86/609/EEC and KB 29/05/2013 and
received approval number EC 2013/157.
Statistics
Data were analyzed with GraphPad Prism 6 software
(GraphPad Software Inc., San Diego, CA, USA). All re-
sults shown represent mean ± standard deviation (S.D.)
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or, for IPMA titers, geometric mean value ± S.D. Sero-
logical titers (IPMA and VN), as well as viral loads, were
log-transformed prior to analysis. Gross pathology scores
and area under the curve (AUC) were analyzed using
the non-parametric Mann Whitney test. Duration was
evaluated by the t-test. Statistical analysis of continuous
data was performed using repeated-measures two-way
analysis of variance (rANOVA), with Bonferroni’s post-
test. Results with P-values ≤ 0.05 were considered statis-
tically significant.
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